Sophiris Bio - Reboundkanditat

http://www.nasdaq.com/de/symbol/sphs/real-time

http://www.finanznachrichten.de/...ichten-aktien/sophiris-bio-inc.htm

http://www.pharmaceutical-business-review.com/...rx302-270515-4586388

Kurs aktuell: SPHS

$1.25


*  

0.365



41.24%  

die 1,6 werden wir bald wiedersehen!
 

 

Schau mal in Deinen alten OPXA-Thread und was da so los ist an der Nasdaq, war mal Dein Beobachtungsshare in 2013.  

http://www.nasdaq.com/de/symbol/sphs/real-time  

http://www.nasdaq.com/de/symbol/sphs/real-time  

Hab im Yahooboard was gelesen.  

 

Financial Results

At March 31, 2015, we had cash, cash equivalents and securities available-for-sale of $17.0 million and net working capital of $15.5 million. We expect that our cash, cash equivalents and securities available-for-sale as of March 31, 2015 will be sufficient to fund our operations through the end of April 2016, assuming that we do not initiate any additional clinical development of PRX302 other than our planned Phase 2a proof of concept trial for low to intermediate risk prostate cancer. We will need to find additional capital to fund a second Phase 3 clinical trial of PRX302 for the treatment of the symptoms of BPH and for any future clinical development of PRX302 for the treatment of localized prostate cancer beyond our planned Phase 2a proof of concept clinical trial.

The Company reported a net loss of $4.3 million ($0.26 per share) for the three months ended March 31, 2015 compared to a net loss of $8.5 million ($0.52 per share) for the three months ended March 31, 2014.


http://seekingalpha.com/pr/...reports-first-quarter-financial-results

Und die Produkte sind auch schon relativ weit:

Sophiris Bio (SPHS +25.4%) commences a Phase 2a proof-of-concept study assessing its lead product candidate, PRX302, in patients with low-to-intermediate risk prostate cancer. The single-center open-label trial will enroll ~20 patients.
PRX302 (topsalysin) is a modified recombinant protein engineered to be selectively activated by an enzyme in the prostate. It kills cancer cells within the prostate without damaging surrounding tissue. It is currently in Phase 3 development for the treatment of symptoms of benign prostatic hyperplasia (enlarged prostate).







Share this with a colleague  

http://stocktwits.com/symbol/SPHS  

sollen anscheinend Ende nächsten Monats kommen...  

...allerdings bei niedrigen Umsätzen :(  

jetzt auch mal aufm schirm  

http://www.prnewswire.com/news-releases/...ry-endpoint-300175745.html  

 

 

Die News kam 14:22 Uhr im Nasdaq-Channel! Les nach. Also du warst später. Soviel dazu.  

Von uns nehmen sie die news!  

warum ist die aktie gestern so stark gelaufen ??
wollte news übersetzen,blicke aber nicht durch,
kurze erklärung wäre hilfreich.


vielen dank
 

da schaust mal wieder ins Depot und siehst hier glatt nen Verdoppler! Geil :)  

http://www.bidnessetc.com/...inc-skyrockets-on-phase-3-study-results/

http://www.finanznachrichten.de/...ichten-aktien/sophiris-bio-inc.htm  

The company mentioned that PRX302 had significantly improved symptoms in men suffering from an enlarged prostate. It did not cause any serious health concerns in any tested patient. Furthermore, it stated that the treatment would be a blockbuster, with potential to garner meaningful annual sales of more than $1 billion.  

vorgestern 180% plus und gestern dachte ich
das die shorties gewinnen da sie den kurs auf 2,45$ drückten,
cirka 14% minus
dann drehte der kurs und ging ins plus 3,20$ 10,34%

daher denke ich das es heute weiter hoch geht.  

16,6 Mio  -  freefloat  wie  hoch  ?

Danke  KH  

http://www.nasdaq.com/de/symbol/sphs/premarket